New iron-based imaging agent significantly improves brain tumor visualization
The U.S. Food and Drug Administration recently approved an iron-based imaging agent shown to significantly improve the visualization of brain tumors on MRI scans.
The agency approved Ferabright (ferumoxytol) for brain tumor imaging in October, but the substance has been utilized in clinical practice elsewhere for decades. Ferumoxytol is an iron-based substance that is used primarily in medications that treat anemia. However, more than 30 years ago, a professor at Oregon Health and Science University began researching the substance’s potential in imaging.
Decades of work led by Edward Neuwelt, MD, a professor and lead researcher in OHSU’s Department of Neurology and founder of OHSU’s Neuro-Oncology Blood-Brain Barrier Program, preceded the new agent’s authorization. He and his team began the process of having ferumoxytol authorized for imaging in 2011.
Since then, Neuwelt and his research team have conducted several clinical trials on the agent’s utility. Those trials revealed that Ferabright offers detailed insight into the biological mechanisms of brain tumors; it enables clinicians to measure tumors’ blood volume, track immune cells and visualize inflammation. All of this information can be used to determine the most effective treatment option for a patient’s unique situation.
“With all brain cancers, but especially glioblastoma, the fastest growing and most aggressive form of brain cancer, it’s crucial we approach treatment with as much efficiency and precision as possible,” Ramon Barajas Jr., MD, professor of diagnostic radiology in the OHSU School of Medicine, said in an OHSU press release. “Patients with brain cancer are often left feeling frustrated trying to understand their tumor’s progression and what the right treatment is,” Barajas said. “Now with a new path forward, we hope patients are provided some hope and comfort in this extremely difficult moment.”
The team has plans to continue their research into the utility of ferumoxytol in other imaging applications, including PET scans and hypoxia imaging.
Ferabright is sold commercially by Massachusetts-based Azurity Pharmacueticals. For more information, click here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.